Sarah has extensive international experience of financing early stage opportunities in the technology sector, with specific focus in life science and healthcare arena.
She has managed a large portfolio of academic programmes, charitable organisations, SMES and larger companies (public and private) to add value and achieve a commercial exit. Before joining the Archangels, Sarah worked in the Innovations Division of the Wellcome Trust, Advent Life Sciences venture team and Parke-Davis Neuroscience Research Centre. Sarah has a PhD in Molecular Neuropharmacology from the University of Aberdeen.
Sarah joined Archangels in March 2016 as Chief Investment Officer and has direct responsibility for number of the portfolio companies, particularly those focused on healthcare.